S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
Log in

NYSE:RDY - Dr.Reddy's Laboratories Stock Price, Forecast & News

$45.26
-0.19 (-0.42 %)
(As of 02/18/2020 04:00 PM ET)
Today's Range
$45.12
Now: $45.26
$45.71
50-Day Range
$40.04
MA: $42.84
$45.85
52-Week Range
$34.67
Now: $45.26
$46.19
Volume129,008 shs
Average Volume219,008 shs
Market Capitalization$7.50 billion
P/E Ratio32.10
Dividend Yield0.57%
Beta0.17
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone91-40-4900-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.23 billion
Cash Flow$2.69 per share
Book Value$12.21 per share

Profitability

Net Income$272 million

Miscellaneous

Employees21,966
Market Cap$7.50 billion
Next Earnings Date5/15/2020 (Estimated)
OptionableOptionable

Receive RDY News and Ratings via Email

Sign-up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.


Dr.Reddy's Laboratories (NYSE:RDY) Frequently Asked Questions

What is Dr.Reddy's Laboratories' stock symbol?

Dr.Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

How were Dr.Reddy's Laboratories' earnings last quarter?

Dr.Reddy's Laboratories Ltd (NYSE:RDY) released its quarterly earnings results on Monday, July, 29th. The company reported $0.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.40 by $0.18. The business had revenue of $558 million for the quarter. Dr.Reddy's Laboratories had a net margin of 9.62% and a return on equity of 18.08%. View Dr.Reddy's Laboratories' Earnings History.

When is Dr.Reddy's Laboratories' next earnings date?

Dr.Reddy's Laboratories is scheduled to release their next quarterly earnings announcement on Friday, May 15th 2020. View Earnings Estimates for Dr.Reddy's Laboratories.

What price target have analysts set for RDY?

7 equities research analysts have issued twelve-month target prices for Dr.Reddy's Laboratories' stock. Their forecasts range from $39.00 to $39.00. On average, they anticipate Dr.Reddy's Laboratories' stock price to reach $39.00 in the next twelve months. This suggests that the stock has a possible downside of 13.8%. View Analyst Price Targets for Dr.Reddy's Laboratories.

What is the consensus analysts' recommendation for Dr.Reddy's Laboratories?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dr.Reddy's Laboratories in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Dr.Reddy's Laboratories.

Has Dr.Reddy's Laboratories been receiving favorable news coverage?

News stories about RDY stock have been trending very positive this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dr.Reddy's Laboratories earned a daily sentiment score of 3.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Dr.Reddy's Laboratories.

Who are some of Dr.Reddy's Laboratories' key competitors?

What other stocks do shareholders of Dr.Reddy's Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dr.Reddy's Laboratories investors own include Siemens (SIEGY), Tata Motors (TTM), Infosys (INFY), Vedanta (VEDL), HDFC Bank (HDB), Merck & Co., Inc. (MRK), GlaxoSmithKline (GSK), Gilead Sciences (GILD), Cummins (CMI) and ICICI Bank (IBN).

Who are Dr.Reddy's Laboratories' key executives?

Dr.Reddy's Laboratories' management team includes the folowing people:
  • Mr. Gunupati Venkateswara Prasad, Co-Chairman, MD, CEO & Member of Management Council (Age 59)
  • Mr. Kallam Satish Reddy, Chairman & Member of the Management Council (Age 52)
  • Mr. Saumen Chakraborty, Pres, CFO, Global Head of IT & Bus. Process Excellence and Member of the Mgmt Council (Age 58)
  • Mr. M. V. Ramana, CEO & Head of Branded Markets - India & Emerging Countries and Member of Management Council (Age 50)
  • Mr. Ganadhish Kamat, Exec. VP, Global Head of Quality & Member of Management Council (Age 56)

Who are Dr.Reddy's Laboratories' major shareholders?

Dr.Reddy's Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.03%), Goldman Sachs Group Inc. (0.54%), State Street Corp (0.44%), Mondrian Investment Partners LTD (0.28%), Bamco Inc. NY (0.23%) and AQR Capital Management LLC (0.20%).

Which institutional investors are selling Dr.Reddy's Laboratories stock?

RDY stock was sold by a variety of institutional investors in the last quarter, including Mitsubishi UFJ Trust & Banking Corp, Mondrian Investment Partners LTD, First Trust Advisors LP, Panagora Asset Management Inc., Amundi Pioneer Asset Management Inc., Marshall Wace North America L.P., Barclays PLC and Sectoral Asset Management Inc.

Which institutional investors are buying Dr.Reddy's Laboratories stock?

RDY stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Renaissance Technologies LLC, Acadian Asset Management LLC, State Street Corp, Schroder Investment Management Group, Vestcor Investment Management Corp, Connor Clark & Lunn Investment Management Ltd. and Sei Investments Co..

How do I buy shares of Dr.Reddy's Laboratories?

Shares of RDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Dr.Reddy's Laboratories' stock price today?

One share of RDY stock can currently be purchased for approximately $45.26.

How big of a company is Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories has a market capitalization of $7.50 billion and generates $2.23 billion in revenue each year. The company earns $272 million in net income (profit) each year or $1.64 on an earnings per share basis. Dr.Reddy's Laboratories employs 21,966 workers across the globe.View Additional Information About Dr.Reddy's Laboratories.

What is Dr.Reddy's Laboratories' official website?

The official website for Dr.Reddy's Laboratories is http://www.drreddys.com/.

How can I contact Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company can be reached via phone at 91-40-4900-2900 or via email at [email protected]


MarketBeat Community Rating for Dr.Reddy's Laboratories (NYSE RDY)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  386 (Vote Underperform)
Total Votes:  661
MarketBeat's community ratings are surveys of what our community members think about Dr.Reddy's Laboratories and other stocks. Vote "Outperform" if you believe RDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Featured Article: Bid-Ask Spread

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel